Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Hyperlipoproteinemias

  Free Subscription


Articles published in Atherosclerosis

Retrieve available abstracts of 116 articles:
HTML format
Text format



Single Articles


    February 2017
  1. WALDMANN E, Vogt A, Crispin A, Altenhofer J, et al
    Effect of mipomersen on LDL-cholesterol in patients with severe LDL-hypercholesterolaemia and atherosclerosis treated by lipoprotein apheresis (The MICA-Study).
    Atherosclerosis. 2017;259:20-25.
    PubMed     Text format     Abstract available


  2. XIANG R, Fan LL, Lin MJ, Li JJ, et al
    The genetic spectrum of familial hypercholesterolemia in the central south region of China.
    Atherosclerosis. 2017;258:84-88.
    PubMed     Text format     Abstract available


    January 2017
  3. WIDHALM K, Benke IM, Fritz M, Geiger H, et al
    Homozygous familial hypercholesterolemia: Summarized case reports.
    Atherosclerosis. 2017;257:86-89.
    PubMed     Text format     Abstract available


  4. BRUCKERT E, Kalmykova O, Bittar R, Carreau V, et al
    Long-term outcome in 53 patients with homozygous familial hypercholesterolaemia in a single centre in France.
    Atherosclerosis. 2017;257:130-137.
    PubMed     Text format     Abstract available


    December 2016
  5. DURST R, Ibe UK, Shpitzen S, Schurr D, et al
    Molecular genetics of familial hypercholesterolemia in Israel-revisited.
    Atherosclerosis. 2016;257:55-63.
    PubMed     Text format     Abstract available


  6. PANES O, Gonzalez C, Hidalgo P, Valderas JP, et al
    Platelet tissue factor activity and membrane cholesterol are increased in hypercholesterolemia and normalized by rosuvastatin, but not by atorvastatin.
    Atherosclerosis. 2016;257:164-171.
    PubMed     Text format     Abstract available


  7. CHRISTENSEN JJ, Osnes LT, Halvorsen B, Retterstol K, et al
    Altered leukocyte distribution under hypercholesterolemia: A cross-sectional study in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;256:67-74.
    PubMed     Text format     Abstract available


  8. BOOT C, Holmes E, Neely RD
    Serum non-HDL cholesterol to apolipoprotein B ratio as a screening test for familial dysbetalipoproteinaemia (Type III hyperlipidaemia) in patients with mixed hyperlipidaemia.
    Atherosclerosis. 2016;255:7.
    PubMed     Text format    


  9. HARALAMBOS K, Ashfield-Watt P, Edwards R, Gingell R, et al
    Five year experience of scoring criteria for familial hypercholesterolaemia (FH) genetic testing in wales: Should the criteria be refined to include age?
    Atherosclerosis. 2016;255:7-8.
    PubMed     Text format    


  10. HONEYCHURCH J, Watson E, Hills A, Dean P, et al
    Validation and utility of a new NGS assay for familial hypercholesterolaemia incorporating 12 LDL-C-raising SNPs.
    Atherosclerosis. 2016;255:6-7.
    PubMed     Text format    


  11. GOYALE A, Jain A, Sharifi M, Gallivan A, et al
    Validation of low density lipoprotein correction factors in a multi-ethnic familial hypercholesterolaemia population at a North London lipid clinic.
    Atherosclerosis. 2016;255:6.
    PubMed     Text format    


  12. SHARIFI M, Jain A, Persaud J, Humphries SE, et al
    Cardiovascular biomarkers in monogenic familial hypercholesterolaemia and polygenic hypercholesterolaemia.
    Atherosclerosis. 2016;255:4.
    PubMed     Text format    


  13. HILLS A, Honeychurch J, Davies J, Robinson C, et al
    4 years' cascade genetic testing for familial hypercholesterolaemia in England - Increased referrals and ascertainment.
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  14. KATE HARALAMBOS K, Whitmore J
    Using pass database and geographic information systems (GIS) to map familial hypercholesterolaemia (FH) diagnoses in England and Wales.
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  15. LUNGLEY J, Jayne Z, Harvey D, Nair DR, et al
    Early identification of familial hypercholesterolaemIa (FH): The prevention of Cardiovascular disease (CVD).
    Atherosclerosis. 2016;255:3.
    PubMed     Text format    


  16. GRITZMACHER L, Bayly GR, Williams M, Hills A, et al
    The critical importance of segregation analysis in the management of patients and their families with suspected familial hypercholesterolaemia: 3 examples from the bristol FH clinic.
    Atherosclerosis. 2016;255:2-3.
    PubMed     Text format    


  17. COZENS A, McMahon S, Purves J, Miedzybrodska Z, et al
    Detection, assessment and treatment of children with familial hypercholesterolaemia in Scotland.
    Atherosclerosis. 2016;255:2.
    PubMed     Text format    


  18. GELLATLY E
    Familial hypercholesterolaemia (FH) - Finding the needle in a haystack in a Scottish population.
    Atherosclerosis. 2016;255:2.
    PubMed     Text format    


  19. ASHFIELD-WATT P, Haralambos K, Edwards R, Townsend D, et al
    Estimation of the prevalence of cholesteryl ester storage disorder (CESD) in a cohort of patients with clinical features of familial hypercholesterolaemia.
    Atherosclerosis. 2016;255:1.
    PubMed     Text format    


    November 2016
  20. FRANCE M, Rees A, Datta D, Thompson G, et al
    HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom.
    Atherosclerosis. 2016 Nov 5. pii: S0021-9150(16)31420.
    PubMed     Text format     Abstract available


    October 2016
  21. SETIA N, Saxena R, Arora A, Verma IC, et al
    Spectrum of mutations in homozygous familial hypercholesterolemia in India, with four novel mutations.
    Atherosclerosis. 2016;255:31-36.
    PubMed     Text format     Abstract available


  22. DANCER M, Caussy C, Di Filippo M, Moulin P, et al
    Lack of evidence for a liver or intestinal miRNA regulation involved in the hypertriglyceridemic effect of APOC3 3'UTR variant SstI.
    Atherosclerosis. 2016;255:6-10.
    PubMed     Text format     Abstract available


  23. CASULA M, Scotti L, Tragni E, Merlino L, et al
    Drug treatment and adherence of subjects <40 years with diagnosis of heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016;254:172-178.
    PubMed     Text format     Abstract available


  24. OGURA M, Makino H, Kamiya C, Yoshimatsu J, et al
    Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion.
    Atherosclerosis. 2016;254:179-183.
    PubMed     Text format     Abstract available


    September 2016
  25. KOSTNER K
    Coronary calcification in familial hypercholesterolemia: Not all about LDL.
    Atherosclerosis. 2016 Sep 28. pii: S0021-9150(16)31377.
    PubMed     Text format    


  26. MARTIN R, Latten M, Hart P, Murray H, et al
    Genetic diagnosis of familial hypercholesterolaemia using a rapid biochip array assay for 40 common LDLR, APOB and PCSK9 mutations.
    Atherosclerosis. 2016;254:8-13.
    PubMed     Text format     Abstract available


  27. MANGILI LC, Mangili OC, Bittencourt MS, Miname MH, et al
    Epicardial fat is associated with severity of subclinical coronary atherosclerosis in familial hypercholesterolemia.
    Atherosclerosis. 2016;254:73-77.
    PubMed     Text format     Abstract available


  28. ARCA M
    Old challenges and new opportunities in the clinical management of heterozygous familial hypercholesterolemia (HeFH): The promises of PCSK9 inhibitors.
    Atherosclerosis. 2016 Sep 2. pii: S0021-9150(16)31315.
    PubMed     Text format     Abstract available


    August 2016
  29. ALONSO R, Mata P, Muniz O, Fuentes-Jimenez F, et al
    PCSK9 and lipoprotein (a) levels are two predictors of coronary artery calcification in asymptomatic patients with familial hypercholesterolemia.
    Atherosclerosis. 2016 Aug 27. pii: S0021-9150(16)31306.
    PubMed     Text format     Abstract available


  30. GRENKOWITZ T, Kassner U, Wuhle-Demuth M, Salewsky B, et al
    Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia.
    Atherosclerosis. 2016;253:88-93.
    PubMed     Text format     Abstract available


    July 2016
  31. WATTS GF, Pang J, Chan DC, Brunt JN, et al
    Angiographic progression of coronary atherosclerosis in patients with familial hypercholesterolaemia treated with non-statin therapy: Impact of a fat-modified diet and a resin.
    Atherosclerosis. 2016;252:82-87.
    PubMed     Text format     Abstract available


  32. ROETERS VAN LENNEP JE
    Knowledge equals health; why all healthcare professionals should know about familial hypercholesterolemia.
    Atherosclerosis. 2016 Jul 30. pii: S0021-9150(16)31229.
    PubMed     Text format    


  33. TORVIK K, Narverud I, Ottestad I, Svilaas A, et al
    Dietary counseling is associated with an improved lipid profile in children with familial hypercholesterolemia.
    Atherosclerosis. 2016;252:21-27.
    PubMed     Text format     Abstract available


  34. SCHOFIELD J, Kwok S, France M, Capps N, et al
    Knowledge gaps in the management of familial hypercholesterolaemia. A UK based survey.
    Atherosclerosis. 2016 Jul 10. pii: S0021-9150(16)30308.
    PubMed     Text format     Abstract available


  35. SJOUKE B, Defesche JC, de Randamie JS, Wiegman A, et al
    Sequencing for LIPA mutations in patients with a clinical diagnosis of familial hypercholesterolemia.
    Atherosclerosis. 2016;251:263-265.
    PubMed     Text format     Abstract available


    May 2016
  36. SILVA PR, Jannes CE, Marsiglia JD, Krieger JE, et al
    Predictors of cardiovascular events after one year of molecular screening for Familial hypercholesterolemia.
    Atherosclerosis. 2016;250:144-150.
    PubMed     Text format     Abstract available


  37. GUARDIOLA M, Cofan M, de Castro-Oros I, Cenarro A, et al
    Corrigendum to "APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis" [Atherosclerosis 240/1 (2015) 98-104].
    Atherosclerosis. 2016 May 12. pii: S0021-9150(16)30169.
    PubMed     Text format    


  38. BANERJEE Y, Santos RD, Al-Rasadi K, Rizzo M, et al
    Targeting PCSK9 for therapeutic gains: Have we addressed all the concerns?
    Atherosclerosis. 2016;248:62-75.
    PubMed     Text format     Abstract available


    April 2016
  39. KRAUZOVA E, Kracmerova J, Rossmeislova L, Malisova L, et al
    Acute hyperlipidemia initiates proinflammatory and proatherogenic changes in circulation and adipose tissue in obese women.
    Atherosclerosis. 2016;250:151-157.
    PubMed     Text format     Abstract available


    March 2016
  40. MICKIEWICZ A, Chmara M, Futema M, Fijalkowski M, et al
    Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland.
    Atherosclerosis. 2016;249:52-58.
    PubMed     Text format     Abstract available


  41. ARAI H, Teramoto T, Daida H, Ikewaki K, et al
    Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2016 Mar 25. pii: S0021-9150(16)30092.
    PubMed     Text format     Abstract available


  42. RALLIDIS LS, Triantafyllis AS, Tsirebolos G, Katsaras D, et al
    Prevalence of heterozygous familial hypercholesterolaemia and its impact on long-term prognosis in patients with very early ST-segment elevation myocardial infarction in the era of statins.
    Atherosclerosis. 2016;249:17-21.
    PubMed     Text format     Abstract available


  43. SANTOS RD
    Homozygous familial hypercholesterolemia: Phenotype rules! Commentary on the study of Raal et al.
    Atherosclerosis. 2016 Mar 14. pii: S0021-9150(16)30090.
    PubMed     Text format    


  44. RAAL FJ, Sjouke B, Hovingh GK, Isaac BF, et al
    Phenotype diversity among patients with homozygous familial hypercholesterolemia: A cohort study.
    Atherosclerosis. 2016 Mar 11. pii: S0021-9150(16)30084.
    PubMed     Text format     Abstract available


  45. STEFFENSEN LB, Conover CA, Bjorklund MM, Ledet T, et al
    Stanniocalcin-2 overexpression reduces atherosclerosis in hypercholesterolemic mice.
    Atherosclerosis. 2016;248:36-43.
    PubMed     Text format     Abstract available


  46. CAUSSY C, Charriere S, Meirhaeghe A, Dallongeville J, et al
    Multiple microRNA regulation of lipoprotein lipase gene abolished by 3'UTR polymorphisms in a triglyceride-lowering haplotype harboring p.Ser474Ter.
    Atherosclerosis. 2016;246:280-6.
    PubMed     Text format     Abstract available


  47. POKHAREL Y, Steinberg L, Chan W, Akeroyd JM, et al
    Case-based educational intervention to assess change in providers' knowledge and attitudes towards the 2013 American College of Cardiology/American Heart Association Cholesterol Management Guideline.
    Atherosclerosis. 2016;246:115-20.
    PubMed     Text format     Abstract available


  48. SCHWEITZER M, Makhoul S, Paliouras M, Beitel LK, et al
    Characterization of the NPC1L1 gene and proteome from an exceptional responder to ezetimibe.
    Atherosclerosis. 2016;246:78-86.
    PubMed     Text format     Abstract available


    February 2016
  49. SANNA C, Stephenne X, Revencu N, Smets F, et al
    Homozygous familial hypercholesterolemia in childhood: Genotype-phenotype description, established therapies and perspectives.
    Atherosclerosis. 2016;247:97-104.
    PubMed     Text format     Abstract available


  50. HERNANDEZ-MIJARES A, Banuls C, Rovira-Llopis S, Diaz-Morales N, et al
    Effects of simvastatin, ezetimibe and simvastatin/ezetimibe on mitochondrial function and leukocyte/endothelial cell interactions in patients with hypercholesterolemia.
    Atherosclerosis. 2016;247:40-47.
    PubMed     Text format     Abstract available


    January 2016
  51. LATET SC, Van Craenenbroeck AH, Van Herck PL, Van Craenenbroeck EM, et al
    A critical view of monocyte subpopulations in human hypercholesterolemia.
    Atherosclerosis. 2016 Jan 14. pii: S0021-9150(16)30021.
    PubMed     Text format    


  52. BAILA-RUEDA L, Perez-Ruiz MR, Jarauta E, Tejedor MT, et al
    Cosegregation of serum cholesterol with cholesterol intestinal absorption markers in families with primary hypercholesterolemia without mutations in LDLR, APOB, PCSK9 and APOE genes.
    Atherosclerosis. 2016;246:202-207.
    PubMed     Text format     Abstract available


  53. ZHENG L, Wu T, Zeng C, Li X, et al
    SAP deficiency mitigated atherosclerotic lesions in ApoE(-/-) mice.
    Atherosclerosis. 2016;244:179-87.
    PubMed     Text format     Abstract available


  54. FARNIER M, Jones P, Severance R, Averna M, et al
    Efficacy and safety of adding alirocumab to rosuvastatin versus adding ezetimibe or doubling the rosuvastatin dose in high cardiovascular-risk patients: The ODYSSEY OPTIONS II randomized trial.
    Atherosclerosis. 2016;244:138-46.
    PubMed     Text format     Abstract available


    December 2015
  55. BESSELING J, Huijgen R, Martin SS, Hutten BA, et al
    Clinical phenotype in relation to the distance-to-index-patient in familial hypercholesterolemia.
    Atherosclerosis. 2015;246:1-6.
    PubMed     Text format     Abstract available


  56. NIIMI M, Yang D, Kitajima S, Ning B, et al
    ApoE knockout rabbits: A novel model for the study of human hyperlipidemia.
    Atherosclerosis. 2015;245:187-193.
    PubMed     Text format     Abstract available


    October 2015
  57. SCHOFIELD J, Bhatnagar D
    The impact of gestational hypercholesterolaemia on origins of disease.
    Atherosclerosis. 2015 Oct 22. pii: S0021-9150(15)30160.
    PubMed     Text format    


  58. RATHOUSKA J, Jezkova K, Nemeckova I, Nachtigal P, et al
    Soluble endoglin, hypercholesterolemia and endothelial dysfunction.
    Atherosclerosis. 2015;243:383-388.
    PubMed     Text format     Abstract available


    September 2015
  59. THOMPSON GR, Seed M, Naoumova RP, Neuwirth C, et al
    Improved cardiovascular outcomes following temporal advances in lipid-lowering therapy in a genetically-characterised cohort of familial hypercholesterolaemia homozygotes.
    Atherosclerosis. 2015;243:328-333.
    PubMed     Text format     Abstract available


  60. VALLEJO-VAZ AJ, Kondapally Seshasai SR, Cole D, Hovingh GK, et al
    Familial hypercholesterolaemia: A global call to arms.
    Atherosclerosis. 2015;243:257-259.
    PubMed     Text format    


  61. IRAWATI D, Mamo JC, Soares MJ, Slivkoff-Clark KM, et al
    Hypertriglyceridemic subjects exhibit an accumulation of small dense chylomicron particles in the fasting state.
    Atherosclerosis. 2015;243:236-241.
    PubMed     Text format     Abstract available


  62. NARVERUD I, van Lennep JR, Christensen JJ, Versmissen J, et al
    Maternal inheritance does not predict cholesterol levels in children with familial hypercholesterolemia.
    Atherosclerosis. 2015;243:155-160.
    PubMed     Text format     Abstract available


  63. SHIN DG, Han SM, Kim DI, Rhee MY, et al
    Clinical features of familial hypercholesterolemia in Korea: Predictors of pathogenic mutations and coronary artery disease - A study supported by the Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;243:53-58.
    PubMed     Text format     Abstract available


  64. BARKAS F, Elisaf M, Milionis H
    Statins decrease the risk of stroke in individuals with heterozygous familial hypercholesterolemia: A systematic review and meta-analysis.
    Atherosclerosis. 2015;243:60-64.
    PubMed     Text format     Abstract available


    August 2015
  65. YU HH, Chen PC, Yang YH, Wang LC, et al
    Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: A nationwide population-based cohort study.
    Atherosclerosis. 2015;243:11-18.
    PubMed     Text format     Abstract available


    July 2015
  66. BOS S, Duvekot MH, Touw-Blommesteijn AC, Verhoeven AJ, et al
    Lipoprotein (a) levels are not associated with carotid plaques and carotid intima media thickness in statin-treated patients with familial hypercholesterolemia.
    Atherosclerosis. 2015;242:226-229.
    PubMed     Text format     Abstract available


  67. PEREIRA C, Miname MH, Makdisse MR, Watanabe C, et al
    Peripheral arterial disease in heterozygous familial hypercholesterolemia.
    Atherosclerosis. 2015;242:174-178.
    PubMed     Text format     Abstract available


  68. STOCK J, Hayes C
    Landmark position paper on paediatric familial hypercholesterolaemia from the EAS Consensus Panel.
    Atherosclerosis. 2015;242:277-280.
    PubMed     Text format    


  69. GALEMA-BOERS JM, Versmissen J, Roeters van Lennep HW, Dusault-Wijkstra JE, et al
    Cascade screening of familial hypercholesterolemia must go on.
    Atherosclerosis. 2015;242:415-417.
    PubMed     Text format     Abstract available


    June 2015
  70. KWON M, Han SM, Kim DI, Rhee MY, et al
    Evaluation of polygenic cause in Korean patients with familial hypercholesterolemia - A study supported by Korean Society of Lipidology and Atherosclerosis.
    Atherosclerosis. 2015;242:8-12.
    PubMed     Text format     Abstract available


  71. BARRIOS C, Pascual J, Otero S, Soler MJ, et al
    Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease.
    Atherosclerosis. 2015;242:37-44.
    PubMed     Text format     Abstract available


  72. WANG X, Guan L, Zhao Y, Lei L, et al
    Plasma cholesterol-lowering activity of dietary dihydrocholesterol in hypercholesterolemia hamsters.
    Atherosclerosis. 2015;242:77-86.
    PubMed     Text format     Abstract available


  73. AHN HY, Kim M, Chae JS, Ahn YT, et al
    Supplementation with two probiotic strains, Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032, reduces fasting triglycerides and enhances apolipoprotein A-V levels in non-diabetic subjects with hypertriglyceridemia.
    Atherosclerosis. 2015;241:649-656.
    PubMed     Text format     Abstract available


  74. MINICOCCI I, Prisco C, Montali A, Di Costanzo A, et al
    Contribution of mutations in low density lipoprotein receptor (LDLR) and lipoprotein lipase (LPL) genes to familial combined hyperlipidemia (FCHL): A reappraisal by using a resequencing approach.
    Atherosclerosis. 2015;242:618-624.
    PubMed     Text format     Abstract available


  75. ITO MK
    Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: A review of the literature.
    Atherosclerosis. 2015 Jun 11. pii: S0021-9150(15)01366.
    PubMed     Text format     Abstract available


  76. BESSELING J, Sjouke B, Kastelein JJ
    Screening and treatment of familial hypercholesterolemia - Lessons from the past and opportunities for the future (based on the Anitschkow Lecture 2014).
    Atherosclerosis. 2015;241:597-606.
    PubMed     Text format     Abstract available


  77. AUSCHER S, Heinsen L, Nieman K, Vinther KH, et al
    Effects of intensive lipid-lowering therapy on coronary plaques composition in patients with acute myocardial infarction: Assessment with serial coronary CT angiography.
    Atherosclerosis. 2015;241:579-587.
    PubMed     Text format     Abstract available


  78. BRAAMSKAMP MJ, Kusters DM, Wiegman A, Avis HJ, et al
    Gonadal steroids, gonadotropins and DHEAS in young adults with familial hypercholesterolemia who had initiated statin therapy in childhood.
    Atherosclerosis. 2015;241:427-432.
    PubMed     Text format     Abstract available


  79. THOMPSON GR
    Obituary of Dr N.B. Myant.
    Atherosclerosis. 2015;240:437-8.
    PubMed     Text format    


  80. GERARDS MC, Terlou RJ, Yu H, Koks CH, et al
    Traditional Chinese lipid-lowering agent red yeast rice results in significant LDL reduction but safety is uncertain - a systematic review and meta-analysis.
    Atherosclerosis. 2015;240:415-23.
    PubMed     Text format     Abstract available


    May 2015
  81. RABACCHI C, Pisciotta L, Cefalu AB, Noto D, et al
    Spectrum of mutations of the LPL gene identified in Italy in patients with severe hypertriglyceridemia.
    Atherosclerosis. 2015;241:79-86.
    PubMed     Text format     Abstract available


  82. POTI F, Ceglarek U, Burkhardt R, Simoni M, et al
    SKI-II--a sphingosine kinase 1 inhibitor--exacerbates atherosclerosis in low-density lipoprotein receptor-deficient (LDL-R-/-) mice on high cholesterol diet.
    Atherosclerosis. 2015;240:212-5.
    PubMed     Text format     Abstract available


  83. MASANA L, Pedro-Botet J, Civeira F
    IMPROVE-IT clinical implications. Should the "high-intensity cholesterol-lowering therapy" strategy replace the "high-intensity statin therapy"?
    Atherosclerosis. 2015;240:161-2.
    PubMed     Text format    


  84. ZHANG T, Zhang C, Zhang Y, Tang F, et al
    Metabolic syndrome and its components as predictors of nonalcoholic fatty liver disease in a northern urban Han Chinese population: a prospective cohort study.
    Atherosclerosis. 2015;240:144-8.
    PubMed     Text format     Abstract available


  85. KOOPAL C, Retterstol K, Sjouke B, Hovingh GK, et al
    Vascular risk factors, vascular disease, lipids and lipid targets in patients with familial dysbetalipoproteinemia: a European cross-sectional study.
    Atherosclerosis. 2015;240:90-7.
    PubMed     Text format     Abstract available


    April 2015
  86. DE BACKER G, Besseling J, Chapman J, Hovingh GK, et al
    Prevalence and management of familial hypercholesterolaemia in coronary patients: An analysis of EUROASPIRE IV, a study of the European Society of Cardiology.
    Atherosclerosis. 2015;241:169-175.
    PubMed     Text format     Abstract available


  87. ODA E
    Associations between serum cholinesterase and incident hyper-LDL cholesterolemia, hypertriglyceridemia and hypo-HDL cholesterolemia as well as changes in lipid levels in a health screening population.
    Atherosclerosis. 2015;241:1-5.
    PubMed     Text format     Abstract available


  88. WATTS GF, Pang J, Santos RD
    Europe aspires to set the record straight on familial hypercholesterolaemia.
    Atherosclerosis. 2015 Apr 20. pii: S0021-9150(15)00234.
    PubMed     Text format    


    March 2015
  89. KIM CH, Mitchell JB, Bursill CA, Sowers AL, et al
    The nitroxide radical TEMPOL prevents obesity, hyperlipidaemia, elevation of inflammatory cytokines, and modulates atherosclerotic plaque composition in apoE mice.
    Atherosclerosis. 2015;240:234-241.
    PubMed     Text format     Abstract available


  90. STEFANUTTI C, Blom DJ, Averna MR, Meagher EA, et al
    The lipid-lowering effects of lomitapide are unaffected by adjunctive apheresis in patients with homozygous familial hypercholesterolaemia - A post-hoc analysis of a Phase 3, single-arm, open-label trial.
    Atherosclerosis. 2015;240:408-414.
    PubMed     Text format     Abstract available


  91. GUARDIOLA M, Cofan M, de Castro-Oros I, Cenarro A, et al
    APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis.
    Atherosclerosis. 2015;240:98-104.
    PubMed     Text format     Abstract available


  92. DESCAMPS O, Tomassini JE, Lin J, Polis AB, et al
    Variability of the LDL-C lowering response to ezetimibe and ezetimibe + statin therapy in hypercholesterolemic patients.
    Atherosclerosis. 2015;240:482-489.
    PubMed     Text format     Abstract available


  93. HARALAMBOS K, Whatley SD, Edwards R, Gingell R, et al
    Clinical experience of scoring criteria for Familial Hypercholesterolaemia (FH) genetic testing in Wales.
    Atherosclerosis. 2015;240:190-196.
    PubMed     Text format     Abstract available


  94. ALIS R, Sanchis-Gomar F, Risso-Ballester J, Perez-Quilis C, et al
    Inhibition of xanthine oxidase to prevent statin-induced myalgia and rhabdomiolysis.
    Atherosclerosis. 2015;239:38-42.
    PubMed     Text format     Abstract available


  95. ODA E
    Cross-sectional and longitudinal associations between serum bilirubin and dyslipidemia in a health screening population.
    Atherosclerosis. 2015;239:31-7.
    PubMed     Text format     Abstract available


    February 2015
  96. ETXEBARRIA A, Benito-Vicente A, Stef M, Ostolaza H, et al
    Activity-associated effect of LDL receptor missense variants located in the cysteine-rich repeats.
    Atherosclerosis. 2015;238:304-12.
    PubMed     Text format     Abstract available


  97. SHIMIZU M, Furusyo N, Mitsumoto F, Takayama K, et al
    Subclinical carotid atherosclerosis and triglycerides predict the incidence of chronic kidney disease in the Japanese general population: results from the Kyushu and Okinawa Population Study (KOPS).
    Atherosclerosis. 2015;238:207-12.
    PubMed     Text format     Abstract available


    January 2015
  98. DONG B, Singh AB, Azhar S, Seidah NG, et al
    High-fructose feeding promotes accelerated degradation of hepatic LDL receptor and hypercholesterolemia in hamsters via elevated circulating PCSK9 levels.
    Atherosclerosis. 2015;239:364-374.
    PubMed     Text format     Abstract available


  99. FUTEMA M, Kumari M, Boustred C, Kivimaki M, et al
    Would raising the total cholesterol diagnostic cut-off from 7.5 mmol/L to 9.3 mmol/L improve detection rate of patients with monogenic familial hypercholesterolaemia?
    Atherosclerosis. 2015;239:295-298.
    PubMed     Text format     Abstract available


  100. LEFORT B, Saheb S, Bruckert E, Giraud C, et al
    Impact of LDL apheresis on aortic root atheroma in children with homozygous familial hypercholesterolemia.
    Atherosclerosis. 2015;239:158-162.
    PubMed     Text format     Abstract available


    December 2014
  101. BELL DA, Pang J, Burrows S, Bates TR, et al
    Effectiveness of genetic cascade screening for familial hypercholesterolaemia using a centrally co-ordinated clinical service: An Australian experience.
    Atherosclerosis. 2014;239:93-100.
    PubMed     Text format     Abstract available


  102. WENG SF, Kai J, Andrew Neil H, Humphries SE, et al
    Improving identification of familial hypercholesterolaemia in primary care: Derivation and validation of the familial hypercholesterolaemia case ascertainment tool (FAMCAT).
    Atherosclerosis. 2014;238:336-343.
    PubMed     Text format     Abstract available


  103. YU K, Dong Q, Mao X, Meng K, et al
    Disruption of the TSLP-TSLPR-LAP signaling between epithelial and dendritic cells through hyperlipidemia contributes to regulatory T-Cell defects in atherosclerotic mice.
    Atherosclerosis. 2014;238:278-288.
    PubMed     Text format     Abstract available


    November 2014
  104. HIDDINK L, Dallinga-Thie GM, Hovingh GK, de Visser MC, et al
    Annexin A5 haplotypes in familial hypercholesterolemia: Lack of association with carotid intima-media thickness and cardiovascular disease risk.
    Atherosclerosis. 2014;238:195-200.
    PubMed     Text format     Abstract available


  105. LAHTINEN AM, Havulinna AS, Jula A, Salomaa V, et al
    Prevalence and clinical correlates of familial hypercholesterolemia founder mutations in the general population.
    Atherosclerosis. 2014;238:64-69.
    PubMed     Text format     Abstract available


  106. JANNES CE, Santos RD, de Souza Silva PR, Turolla L, et al
    Familial hypercholesterolemia in Brazil: Cascade screening program, clinical and genetic aspects.
    Atherosclerosis. 2014;238:101-107.
    PubMed     Text format     Abstract available


  107. FADINI GP, Simoni F, Cappellari R, Vitturi N, et al
    Pro-inflammatory monocyte-macrophage polarization imbalance in human hypercholesterolemia and atherosclerosis.
    Atherosclerosis. 2014;237:805-808.
    PubMed     Text format     Abstract available


    October 2014
  108. MOLLAKI V, Progias P, Drogari E
    Familial Hypercholesterolemia in Greek children and their families: Genotype-to-phenotype correlations and a reconsideration of LDLR mutation spectrum.
    Atherosclerosis. 2014;237:798-804.
    PubMed     Text format     Abstract available


    September 2014
  109. FOLSE HJ, Goswami D, Rengarajan B, Budoff M, et al
    Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study.
    Atherosclerosis. 2014;236:154-61.
    PubMed     Text format     Abstract available


    August 2014
  110. AMINI N, Boyle JJ, Moers B, Warboys CM, et al
    Requirement of JNK1 for endothelial cell injury in atherogenesis.
    Atherosclerosis. 2014;235:613-8.
    PubMed     Text format     Abstract available


  111. BORRELL-PAGES M, Romero JC, Badimon L
    Cholesterol modulates LRP5 expression in the vessel wall.
    Atherosclerosis. 2014;235:363-70.
    PubMed     Text format     Abstract available


  112. ODA E
    A decrease in total bilirubin predicted hyper-LDL cholesterolemia in a health screening population.
    Atherosclerosis. 2014;235:334-8.
    PubMed     Text format     Abstract available


    July 2014
  113. PRENNER SB, Mulvey CK, Ferguson JF, Rickels MR, et al
    Very low density lipoprotein cholesterol associates with coronary artery calcification in type 2 diabetes beyond circulating levels of triglycerides.
    Atherosclerosis. 2014;236:244-250.
    PubMed     Text format     Abstract available


    June 2014
  114. HOLLIE NI, Konaniah ES, Goodin C, Hui DY, et al
    Group 1B phospholipase A(2) inactivation suppresses atherosclerosis and metabolic diseases in LDL receptor-deficient mice.
    Atherosclerosis. 2014;234:377-80.
    PubMed     Text format     Abstract available


    April 2014
  115. KHAN IM, Dai Perrard XY, Perrard JL, Mansoori A, et al
    Attenuated adipose tissue and skeletal muscle inflammation in obese mice with combined CD4+ and CD8+ T cell deficiency.
    Atherosclerosis. 2014;233:419-28.
    PubMed     Text format     Abstract available


    January 2014
  116. PURSNANI S, Diener-West M, Sharrett AR
    The effect of aging on the association between coronary heart disease risk factors and carotid intima media thickness: An analysis of the Atherosclerosis Risk in Communities (ARIC) cohort.
    Atherosclerosis. 2014;233:441-446.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hyperlipoproteinemias is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: